Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 245 | 36 | 203 |
| Samples | 102 | 20 | 78 |
| Peptides | 84 | 20 | 69 |
Function
PRDX5 · Peroxiredoxin 5
This gene encodes a member of the peroxiredoxin family of antioxidant enzymes, which reduce hydrogen peroxide and alkyl hydroperoxides. The encoded protein interacts with peroxisome receptor 1 and plays an antioxidant protective role in different tissues under normal conditions and during inflammatory processes. The use of alternate transcription start sites is thought to result in transcript variants that use different in-frame translational start codons to generate isoforms that are targeted to the mitochondrion (isoform L) or peroxisome/cytoplasm (isoform S). Multiple related pseudogenes have been defined for this gene. [provided by RefSeq, Nov 2017].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 72 amino-acid changes on canonical ENST00000265462 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PRDX5 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PRDX5 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chordoma | 2/7 29% | 1/13 8% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Endometrial Carcinoma | 1/42 2% | 6/612 1% |
| Hodgkins Lymphoma | 1/16 6% | 0/122 0% |
| Bladder Carcinoma | 0/58 0% | 7/956 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 10/1592 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Colorectal Carcinoma | 2/143 1% | 11/3239 0% |
| Melanoma | 2/210 1% | 5/1899 0% |
| Gastric Carcinoma | 1/74 1% | 5/1809 0% |
| Ewings Sarcoma | 0/63 0% | 1/262 0% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 2/1390 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Prostate Carcinoma | 2/13 15% | 2/2105 0% |
| Hepatocellular Carcinoma | 0/46 0% | 4/2210 0% |
| Breast Carcinoma | 2/144 1% | 4/3264 0% |
| Head and Neck Carcinoma | 0/85 0% | 3/1574 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Other Solid Cancers | 0/94 0% | 2/1515 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 3/2550 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 1/2534 0% |
| Kidney Carcinoma | 0/85 0% | 2/1862 0% |
| Ovarian Carcinoma | 0/109 0% | 1/998 0% |
| Other Blood Cancers | 0/61 0% | 1/2725 0% |
Mutation Distribution
Where PRDX5 is mutated · all tissues, split by cell line vs tissue
How many mutations in PRDX5 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 245 mutations in PRDX5
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|